Participated · Series B · Apr 2024

Miach Orthopaedics develops the Bridge-Enhanced ACL Restoration (BEAR®) Implant, a bio‑engineered product that facilitates healing of torn anterior cruciate ligaments rather than replacing them. The BEAR Implant acts as a bridge between ACL ends, uses a small amount of the patient’s blood to promote healing, and is resorbed as the ligament repairs. It received De Novo FDA approval in December 2020 and is indicated for skeletally mature patients (14+) with a complete ACL rupture and an ACL stump attached to the tibia. The company reports the BEAR Implant has been used to treat nearly 3,000 patients. Miach says the technology is a paradigm shift from ACL reconstruction because it avoids graft harvest or donor tendons and preserves the ACL’s native attachments. Current priorities include U.S. commercial expansion and clinical initiatives such as the Bridge Registry to gather real‑world outcomes. The company is privately held and located in Westborough, Massachusetts. Miach Orthopaedics is a privately held company in Westborough, Massachusetts, focused on bio-engineered surgical implants for connective tissue restoration, initially commercializing the BEAR Implant for ACL repair. The BEAR Implant is a bridge-enhanced, bio‑engineered device that, when combined with a small amount of the patient’s blood, facilitates healing of a torn ACL and is resorbed as the ligament heals. The device received De Novo FDA approval in December 2020 and is the first medical technology with Level 1 clinical evidence showing it enables the body to heal a torn ACL. Commercial launch began in fall 2021; more than 500 patients have been treated with the BEAR Implant commercially. The company says the BEAR procedure avoids harvesting or using donor tendon grafts and preserves the ACL’s original attachments. The recent financing will fund ongoing operations and expand the U.S. commercial rollout to bring ACL restoration to more patients. MIACH Orthopaedics is focused on the Bridge-Enhanced® ACL Repair (BEAR®), a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of torn anterior cruciate ligaments. The BEAR technology has been tested in nearly 100 human patients under an FDA Investigational Device Exemption (IDE). Preclinical studies and the company’s clinical work suggest the BEAR procedure avoids graft harvest and may lower long-term arthritis risk versus conventional ACL reconstruction. MIACH plans to use new funding to accelerate manufacturing capabilities and continue U.S. clinical trials of BEAR. The company has received initial research funding from the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. MIACH is a privately held company located in Boston, Massachusetts.

Participated · Series C · Jan 2019

Trice Medical develops a portable, tablet-based imaging platform that combines a disposable needle camera (mi-eye™) with a high-quality ultrasound transducer (mi-ultra™) for orthopedic procedures. The company’s products are intended to enable procedures outside of traditional imaging suites. Since 2019, Trice has acquired Seg-WAY™ Orthopedics and Tenex Health, expanding its capabilities in minimally invasive ultrasonic technology for chronic pain treatment. The company is led by CEO and President Mark Foster. Trice announced a Series D financing whose amount was not disclosed and entered a strategic arrangement with Bioventus as part of the transaction. As described in the articles, Trice and Bioventus will pursue co-development to explore integration of their technologies to accelerate adoption of both companies’ offerings. Trice Medical, based in Malvern, Pa., makes integrated, camera-enabled and ultrasound platforms for minimally invasive orthopedic diagnostics, including the mi-eye 2 disposable arthroscopy camera and the mi-ultra 15 MHz handheld ultrasound transducer. The company’s Dynamic Imaging Platform combines the mi-eye technology with the mi-ultra on a single portable platform. Trice says its mission is to provide more immediate and definite patient care, reduce false reads from indirect modalities, and significantly lower healthcare costs. The company plans to expand worldwide commercialization of mi-eye 2 and mi-ultra and to accelerate development of its minimally invasive product portfolio. Management described 2019 as a transformational year, with plans to expand sales globally, launch several new products and announce large multinational partnerships. Trice Medical, based in King of Prussia, Pa., has developed the mi-eye2, a fully integrated camera-enabled handheld diagnostic scope that lets physicians diagnose joint injuries from the office. The mi-eye2 uses a disposable needle embedded with a wide-angle camera lens and improved vision quality to provide a non-invasive, more complete diagnosis. The device is currently being used by nearly 100 physician practices across 25 states. The company intends to use recent funding to accelerate and expand U.S. market penetration, support R&D, and grow sales and marketing. Trice Medical also plans to pursue key international regulatory approvals. Jeffrey O’Donnell, Sr. serves as President and CEO. The company has raised $40.9M to date. Trice Medical develops micro-invasive diagnostic tools for in-office procedures. Its core product, the mi-eye, is a fully disposable, single-use visualization device that uses a standard 14-gauge needle with an integrated camera and light to perform diagnostic arthroscopy during the initial consultation. An LCD tablet running Android OS attaches via a data cable to display images from the mi-eye needle. The company closed an $18.1M Series B financing led by HealthQuest Capital. Following the round, Trice appointed Craig Carra as its newly created Chief Financial Officer. Carra is a medical device and services veteran with roughly 20 years of experience and prior roles at Coopers & Lybrand, Surgical Laser Technologies, PhotoMedex and Ella Health. Trice Medical's core product, mi-eye, is a fully disposable, single‑use visualization device that integrates a camera and light source into a standard 14‑gauge needle to perform diagnostic arthroscopy in the physician's office. The device connects via a data cable to a separate Android‑based LCD tablet and is delivered sterile and ready for immediate use. Trice positions mi-eye to provide faster, more definitive, and less expensive diagnoses by eliminating false reads from indirect modalities such as MRI. The company received FDA 510(k) clearance for mi-eye, which it described as a key regulatory milestone. Trice plans to apply for CE Mark in Europe and seek approvals in other countries, and intends a limited marketing launch beginning in Q4 2014 while building inventory and developing marketing and educational programs. Financially, the company received the balance of cash related to an $11.6M Series B financing led by Safeguard Scientifics.

Participated · Equity · Dec 2016

OrthoSpace develops InSpace™, an orthopedic biodegradable balloon system used as a minimally invasive treatment for rotator cuff injuries. The device is marketed in Europe, Israel, Russia and Hong Kong, where about 10,000 balloons have been implanted. The procedure can be performed in an outpatient setting and is intended to reduce shoulder pain and improve range of motion. The company is led by CEO Itay Barnea. OrthoSpace is pursuing a US Investigational Device Exemption (IDE) FDA study and plans to expand commercial activities in Europe, South America and Asia. The recent financing is intended to support the IDE study, international commercial build-out and working capital. OrthoSpace provides InSpace, an orthopedic biodegradable balloon system designed to treat severe rotator cuff tears. The device is CE Marked and is commercialized in Europe and Israel. The company has been granted an Investigational Device Exemption (IDE) to initiate a pivotal human clinical study in the United States. Leadership includes CEO Itay Barnea and Co‑Founder and Medical Director Assaf Dekel MD. OrthoSpace recently completed a financing of undisclosed amount to support continued market adoption, its clinical study programs and entry into emerging markets. The company is based in Caesarea, Israel.

Led · Series B · Feb 2015

Michelson Diagnostics develops, manufactures and markets the VivoSight multi-beam Optical Coherence Tomography (OCT) scanner, a point-of-care, real-time tissue imaging device that provides continuous images of the epidermis and superficial dermis. The company holds CE and TGA regulatory clearances and has FDA 510(k) approval in the United States. It plans to use new funding to expand its commercial presence in Germany and to launch the VivoSight OCT system more broadly. Ongoing clinical work includes a US multi-centre clinical biopsy avoidance study the company intends to complete. Michelson is exploring further applications of the VivoSight system in wound care and dentistry. The company was founded in 2006, is led by Chairman Brian Howlett, has 18 employees and maintains offices in Germany and the USA. Michelson Diagnostics develops multi-beam Optical Coherence Tomography technology using an advanced laser scanner to produce high-resolution images of tissue. Its core product, the VivoSight OCT system, is focused on non-invasive diagnosis and monitoring of cutaneous and epithelial conditions including non-melanoma skin cancer (NMSC). The VivoSight system has regulatory clearance in Europe, the USA and Australia for use by trained clinicians. The company plans to expand VivoSight sales in Germany, develop a second-generation VivoSight with enhanced functionality, and initiate US market access with a planned pilot clinical study. Michelson Diagnostics was founded in 2006 and is led by CEO Jon Holmes; it currently has 18 employees and sales offices in Germany and the USA. The company is based in Orpington, Kent, UK. Michelson Diagnostics is a Kent, UK-based medical device company that has developed and brought to market the VivoSight scanning device for non-melanoma skin cancer. The VivoSight scanner enables clinicians to see under the skin surface in real time to help decide whether to treat a lesion, which treatment to use, and to map how far a tumour has spread so surgery can conserve healthy tissue. Led by CEO Jon Holmes, the company has an installed base of VivoSight skin cancer laser scanners and is expanding commercial operations. Michelson received a £607k investment as an extension to a £1.92M investment from October 2011. Backers on this round include existing shareholders Octopus Investments, Catapult Venture Managers and individual investors, including some London Business Angels which invested £332k. The company intends to use the proceeds to expand sales and support infrastructure in the USA and Europe to support its growing installed base. Michelson Diagnostics develops multi-beam optical coherence tomography (OCT) instruments for dermatology, including its VivoSight scanner. The VivoSight is based on the company’s patented multi-beam OCT technology and allows dermatologists to see below the surface of the skin to gather clinical information. The scanner has CE and FDA regulatory clearance and has entered commercial service at dermatology clinics in the USA and Germany. Founded in 2006 and led by CEO Jon Holmes, the company is based in Kent, England, with US operations in South Dartmouth, Massachusetts. In November 2011 it received a £1.912m investment to expand sales and support infrastructure in the USA and Europe. Backers include Octopus Investments, Catapult Venture Managers and individual investors from London Business Angels. Michelson Diagnostics, based in Orpington, UK, has developed a laser scanning technology to image skin and other surface tissue at much higher resolution. Its core product, the VivoSight scanner, enables clinicians to see beneath the skin in real time to inform treatment decisions and assess tumour spread so surgery can conserve healthy tissue. The device has won CE and FDA regulatory clearance for clinical use in Europe and the USA and is being evaluated by skin cancer specialists at their clinics. The company received a second investment of £300k from Octopus Investments, adding to an initial £1.7M investment in October 2010. The £300k is intended to fund scanner manufacturing and to grow sales infrastructure in the UK and USA. The disclosed funding from these investments is roughly £2.0M to support product commercialization and sales expansion.